Clinical Trial Update: Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer [Phase 2]

View source ↗

Summary

This ClinicalTrials.gov update notes the termination of a Phase 2 neoadjuvant trial of anastrozole combined with vandetanib for postmenopausal hormone receptor-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ARIMIDEX (anastrozole)
• Caprelsa (vandetanib)

Snippet

Sponsor: Stanford University | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-02-07